UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
2026-10-09 02:15
•Reuben Gregg Brewer •The Motley Fool
•••• •• Axe Cap view
Is Novo Nordisk a Value Trap or a Patient Investor’s Play?
While UBS warns against Novo Nordisk’s near-term challenges, its solid dividend and R&D could pay off down the line.
UBS calls Novo Nordisk a value trap, favoring Eli Lilly’s near-term growth in GLP-1 weight-loss drugs. That’s a fair take if you’re chasing quick wins. Lilly’s pipeline is broader, and it’s leading the race now. But Novo Nordisk isn’t a dead horse yet. It still owns a strong first-mover position in GLP-1s, and its 4.7% dividend yield offers a cushion for patient investors. In South Africa, this plays into USD/ZAR risk — a drug sector selloff could weigh on the rand given global risk sentiment, but long-term stability with dividends remains attractive. If you’re comfortable waiting 5 to 10 years for Novo Nordisk’s turnaround, it’s worth watching. The risk? Lilly could widen its lead or new competitors might erode GLP-1 dominance faster than expected. this is just our opinion and not financial advice
Trim exposure to Novo Nordisk for now, focusing on Lilly if you want growth. Hold Novo only if you’re aiming for income and long-term payoff. Watch USD/ZAR for risk signals tied to biotech sector shifts.
- NVO
- LLY
- USD/ZAR
- Eli Lilly extending market lead longer than expected
- Sudden GLP-1 competition from new entrants
- Rand volatility impacting offshore investment returns
5/10
UBS analyst Michael Yee labeled Novo Nordisk a value trap, favoring Eli Lilly's growth prospects in the GLP-1 drug market. However, the article argues that while Eli Lilly currently leads, Novo Nordisk's strong R&D capabilities and 4.7% dividend yield make it a potential long-term turnaround story for patient investors willing to wait 5-10 years for recovery.
Our take is based on reporting first published by The Motley Fool.